Traphaco Joint Stock Company

HOSE:TRA Stock Report

Market Cap: ₫3.2t

Traphaco Past Earnings Performance

Past criteria checks 2/6

Traphaco has been growing earnings at an average annual rate of 8.3%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.7% per year. Traphaco's return on equity is 14.9%, and it has net margins of 8%.

Key information

8.3%

Earnings growth rate

8.5%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate6.7%
Return on equity14.9%
Net Margin8.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Traphaco makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:TRA Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,318,464184,846927,8870
30 Jun 242,330,603211,240904,4230
31 Mar 242,227,617212,103897,8550
31 Dec 232,299,235229,440911,5610
30 Sep 232,292,623216,324954,0420
30 Jun 232,320,994223,521977,6640
31 Mar 232,394,035226,2741,023,0940
31 Dec 222,398,918235,185992,6180
30 Sep 222,389,723253,883945,9020
30 Jun 222,353,551246,853905,6190
31 Mar 222,313,116237,067845,9630
31 Dec 212,160,840209,901820,8550
30 Sep 212,191,557204,915854,5410
30 Jun 212,082,080188,623831,3860
31 Mar 211,988,241173,516794,5850
31 Dec 201,908,870172,611762,3420
30 Sep 201,846,090176,937745,5350
30 Jun 201,762,663159,869714,8850
31 Mar 201,736,640139,298758,7120
31 Dec 191,710,439134,818712,5890
30 Sep 191,703,913139,347676,4670
30 Jun 191,795,932142,720711,5530
31 Mar 191,798,990139,146693,0290
31 Dec 181,798,350137,713707,9810
30 Sep 181,825,079148,223732,2720
30 Jun 181,809,549169,668708,4770
31 Mar 181,833,899207,822691,6080
31 Dec 171,870,442217,140717,5980
30 Sep 171,806,911189,374671,9740
30 Jun 171,838,707186,362668,6080
31 Mar 171,890,096180,072655,4130
31 Dec 161,998,334189,062646,2570
30 Sep 162,034,951205,819616,7800
30 Jun 162,029,519198,536604,4290
31 Mar 162,023,193181,332599,2980
31 Dec 151,974,002163,210591,3990
30 Sep 151,958,262148,334575,7800
30 Jun 151,893,579145,606552,9000
31 Mar 151,821,132145,739517,6850
31 Dec 141,650,722132,427459,9670
30 Sep 141,538,937125,018456,2320
30 Jun 141,552,664125,497455,9610
31 Mar 141,537,105134,616446,7190

Quality Earnings: TRA has high quality earnings.

Growing Profit Margin: TRA's current net profit margins (8%) are lower than last year (9.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TRA's earnings have grown by 8.3% per year over the past 5 years.

Accelerating Growth: TRA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: TRA had negative earnings growth (-14.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).

Return on Equity

High ROE: TRA's Return on Equity (14.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 11:17
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Traphaco Joint Stock Company is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Minh DangSSI Securities Corporation
Barry WeisblattVPS Securities JSC, Research Division